Difference between revisions of "Disclosure statement (from DOI: 10.1080/22221751.2020.1735265) (Q8419)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
 
(15 intermediate revisions by the same user not shown)
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank
Property / Has Sectioning
 +
Property / Has Sectioning: Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265) / rank
 +
Normal rank

Latest revision as of 20:52, 14 May 2020

Publication: "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection" in the journal Emerg Microbes Infect (2020); DOI: 10.1080/22221751.2020.1735265
Language Label Description Also known as
English
Disclosure statement (from DOI: 10.1080/22221751.2020.1735265)
Publication: "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection" in the journal Emerg Microbes Infect (2020); DOI: 10.1080/22221751.2020.1735265

    Statements

    instance of
    Segment
    0 references
    Has Sectioning
     

    Sitelinks

    Retrieved from "http://wikibase.slis.ua.edu/w/index.php?title=Item:Q8419&oldid=194491"